Enhanced Genomics and The ALBORADA Institute partner to accelerate Alzheimer's drug discovery

Enhanced Genomics has formed a partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge to accelerate Alzheimer’s drug discovery.

Funded by Alzheimer’s Research UK, The ALBORADA Drug Discovery Institute is developing the next generation of treatments for the diseases that cause dementia.

Enhanced Genomics’ 3D multi-omics platform has been harnessed to rapidly identify multiple novel therapeutic targets that were undetectable using conventional genomic approaches. The partnership has already yielded novel drug targets for Alzheimer's disease.

Under the partnership agreement, Enhanced utilised its proprietary Promoter Capture Hi-C technology, multi-omic data, and expert knowledge to map long-range chromatin interactions, revealing crucial gene regulatory-mechanisms involved in driving Alzheimer's disease.

This approach identified several novel targets, as well as corroborating targets already reported in the literature, opening new avenues for therapeutic intervention.

"Our partnership with The ALBORADA Drug Discovery Institute showcases the transformative power of 3D multi-omics in drug discovery," said Dr Dan Turner, CSO of Enhanced Genomics. "By harnessing our unique platform, we have not only accelerated the target discovery process but also unveiled new therapeutic possibilities by harnessing the full potential of the non-coding genome. We’re confident that we can improve both timescales and success rates of target ID and drug development using 3D multi-omics."

Dr John Skidmore, CSO at The ALBORADA Drug Discovery Institute, said that by using Enhanced’s technology “we have gained new actionable targets”, adding: “This could significantly advance our ability to develop effective treatments for Alzheimer's disease.”